Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) New England Journal of Medicine In 3,297 patients with T2D, semaglutide reduced major adverse cardiovascular events by 26% versus placebo over 2.1 years (HR 0.74), driven by 39% stroke reduction and 26% nonfatal MI reduction
History of Medullary Thyroid Carcinoma (MTC) or MEN 2 Individuals with a history of medullary thyroid carcinoma (a type of thyroid cancer) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid semaglutide due to the potential risk of worsening these conditions
The same goes for Wegovy , which contains the same active ingredient as Ozempic (semaglutide) but in higher dosage strengths
If you have diabetes and already take a different medication, talk to your physician about acceptable (and safe) combinations of diabetes medication.
If someone experiences incomplete benefits while titrating up liraglutide doses, we may switch to semaglutide after reaching the maximum dose, says Watson
Monitor fasting glucose, HbA1c, lipid panel, B12 levels, thyroid function, liver enzymes, and kidney function
